يعرض 91 - 100 نتائج من 431 نتيجة بحث عن '"Barry H. Greenberg"', وقت الاستعلام: 0.81s تنقيح النتائج
  1. 91
  2. 92

    المساهمون: Cardiovascular Centre (CVC)

    المصدر: International Journal of Cardiology, 253, 91-96. ELSEVIER IRELAND LTD

  3. 93
  4. 94
  5. 95
  6. 96
  7. 97

    المساهمون: Centre d'investigation clinique [Nancy] (CIC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Défaillance Cardiovasculaire Aiguë et Chronique (DCAC), Department of Medicine [San Diego], University of California [San Diego] (UC San Diego), University of California-University of California, National Heart & Lung Institute, Imperial College London, Center for Cardiovascular Innovation, Feinberg School of Medicine, Northwestern University [Evanston]-Northwestern University [Evanston], University Medical Center Groningen [Groningen] (UMCG), Brigham and Women's Hospital [Boston], University Medical Center Göttingen (UMG), Janssen Research & Development, Cardiovascular Centre (CVC)

    المصدر: European Journal of Heart Failure
    European Journal of Heart Failure, Oxford University Press (OUP), 2015, 17 (7), pp.735-742. ⟨10.1002/ejhf.266⟩
    European journal of heart failure, vol 17, iss 7
    European Journal of Heart Failure, 17(7), 735-742. Wiley

    مصطلحات موضوعية: Cardiac & Cardiovascular Systems, Exacerbation, IMPACT, Myocardial Infarction, Administration, Oral, heart failure, Coronary Artery Disease, Cardiorespiratory Medicine and Haematology, antithrombotic, Cardiovascular, Coronary artery disease, Rivaroxaban, Risk Factors, MESH: Risk Factors, MESH: Double-Blind Method, Prospective Studies, MESH: Coronary Artery Disease, Myocardial infarction, THROMBIN GENERATION, rivaroxaban, OUTCOMES, Ejection fraction, MESH: Research Design, Atrial fibrillation, thrombin, Thrombosis, 3. Good health, Stroke, Survival Rate, MESH: Myocardial Infarction, Heart Disease, Research Design, 6.1 Pharmaceuticals, Administration, MESH: Administration, Oral, Cardiology, Patient Safety, MESH: Factor Xa Inhibitors, Cardiology and Cardiovascular Medicine, Life Sciences & Biomedicine, MESH: Rivaroxaban, coronary artery disease, medicine.drug, Oral, medicine.medical_specialty, MESH: Survival Rate, Clinical Trials and Supportive Activities, ANTICOAGULANTS, COAGULATION, 1102 Cardiovascular Medicine And Haematology, MESH: Stroke, WARFARIN, Double-Blind Method, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Clinical Research, Internal medicine, MANAGEMENT, medicine, Humans, Heart Disease - Coronary Heart Disease, Heart Failure, Science & Technology, MESH: Humans, business.industry, MORTALITY, Evaluation of treatments and therapeutic interventions, medicine.disease, R1, MESH: Prospective Studies, ASPIRIN, Cardiovascular System & Hematology, Heart failure, MESH: Heart Failure, Cardiovascular System & Cardiology, business, Factor Xa Inhibitors

    وصف الملف: application/pdf

  8. 98
  9. 99
  10. 100

    المساهمون: Cardiovascular Centre (CVC)

    المصدر: Clinical research in cardiology : official journal of the German Cardiac Society, vol 106, iss 6
    Clinical Research in Cardiology
    Clinical Research in Cardiology, 106(6), 444-456. SPRINGER HEIDELBERG

    وصف الملف: application/pdf